Prognostic properties of the baseline prostate-specific antigen value-insights from the European randomized study of screening for prostate cancer.
作者信息
Scherer Thomas Paul, Poyet Cédric
机构信息
Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
出版信息
Transl Androl Urol. 2024 Mar 31;13(3):473-475. doi: 10.21037/tau-23-606. Epub 2024 Mar 11.
Abstract
摘要
相似文献
1
Prognostic properties of the baseline prostate-specific antigen value-insights from the European randomized study of screening for prostate cancer.
Transl Androl Urol. 2024 Mar 31;13(3):473-475. doi: 10.21037/tau-23-606. Epub 2024 Mar 11.
2
Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Int J Cancer. 2023 Feb 15;152(4):672-678. doi: 10.1002/ijc.34274. Epub 2022 Sep 15.
3
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.
4
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Eur Urol. 2019 Mar;75(3):399-407. doi: 10.1016/j.eururo.2018.08.032. Epub 2018 Sep 17.
5
Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Urology. 2001 Jan;57(1):83-90. doi: 10.1016/s0090-4295(00)00863-3.
6
Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening.
Cancer Manag Res. 2016 May 10;8:45-7. doi: 10.2147/CMAR.S98326. eCollection 2016.
7
Risk of developing prostate cancer in the future: overview of prognostic biomarkers.
Urology. 2009 May;73(5 Suppl):S21-7. doi: 10.1016/j.urology.2009.02.022.
8
A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Eur Urol. 2015 Oct;68(4):591-7. doi: 10.1016/j.eururo.2014.04.005. Epub 2014 Apr 18.
9
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.
10
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Eur Urol. 2009 Feb;55(2):385-92. doi: 10.1016/j.eururo.2008.02.046. Epub 2008 Mar 11.
本文引用的文献
1
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium.
Eur Urol. 2024 Jul;86(1):20-26. doi: 10.1016/j.eururo.2023.04.028. Epub 2023 May 9.
2
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Eur Urol. 2023 Nov;84(5):503-509. doi: 10.1016/j.eururo.2023.03.031. Epub 2023 Apr 21.
3
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.
4
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
J Clin Oncol. 2016 Aug 10;34(23):2705-11. doi: 10.1200/JCO.2016.66.7527. Epub 2016 Jun 13.
5
Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity.
Epidemiology. 2016 Jul;27(4):531-7. doi: 10.1097/EDE.0000000000000499.
6
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.
7
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.
8
The impact of PLCO control arm contamination on perceived PSA screening efficacy.
Cancer Causes Control. 2012 Jun;23(6):827-35. doi: 10.1007/s10552-012-9951-8. Epub 2012 Apr 10.
9
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
Clin Cancer Res. 2010 Sep 1;16(17):4374-81. doi: 10.1158/1078-0432.CCR-10-1328. Epub 2010 Aug 24.
10
Screening and prostate-cancer mortality in a randomized European study.
N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.
Zotero 插件